Needham Assigns a Buy Rating on Generation Bio (GBIO)

Needham analyst Gil Blum assigned a Buy rating to Generation Bio (GBIOResearch Report) today and set a price target of $50.00. The company’s shares closed last Tuesday at $30.71.

According to TipRanks.com, Blum is ranked #6387 out of 7499 analysts.

Currently, the analyst consensus on Generation Bio is a Strong Buy with an average price target of $44.50.

See today’s analyst top recommended stocks >>

Generation Bio’s market cap is currently $1.71B and has a P/E ratio of -11.60. The company has a Price to Book ratio of 6.83.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Generation Bio Co is a genetics medicine company which is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina related diseases.